A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE ESCALATION STUDY OF SGR-1505 AS MONOTHERAPY IN SUBJECTS WITH MATURE B-CELL MALIGNANCIES

Clinical Trial Grant

Duke Scholars

Principal Investigator Matthew Stuart McKinney Medicine, Hematologic Malignancies and Cellular Therapy

Administered By

Duke Cancer Institute

Awarded By

Schrodinger, Inc.

Start Date

March 1, 2024

End Date

March 14, 2029

Administered By

Duke Cancer Institute

Awarded By

Schrodinger, Inc.

Start Date

March 1, 2024

End Date

March 14, 2029